
FDA Approves STS101 (Dihydroergotamine) Nasal Powder for Acute Treatment of Migraine
Satsuma Pharmaceuticals has announced the US FDA's approval of STS 101 (dihydroergotamine [DHE]) nasal powder for the acute treatment of migraine with or without aura in adults. STS101, to be marketed as Atzumi, it is the first DHE nasal powder product …